Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 14/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | PGR | P06401 | 10/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755290 | 0.90 | NR3C1 (0.54) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL3743370 | 0.89 | NR3C1 (0.53) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL4555711 | 0.89 | NR3C1 (0.54) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL3710020 | 0.88 | NR3C1 (0.52) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL4447862 | 0.86 | NR3C1 (0.71) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL3746290 | 0.85 | NR3C1 (0.52) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL3688034 | 0.84 | NR3C1 (0.67) | NR3C1NR3C2PGR | |
| SCHEMBL291202 | 0.81 | NR3C1 (0.77) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL4556027 | 0.80 | NR3C1 (0.54) | NR3C1NR3C2CYP3A4PGR | |
| SCHEMBL4556423 | 0.80 | NR3C1 (0.52) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | 1261229 B.C. LTD. (CA) | 2011-11-17 | — | — | US | disclosed |
| EP-2056799-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | Bausch & Lomb Incorporated (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885CYP3A4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.